chemXplore tracks 5 projects in Puerto Rico, of which 5 are active.
Of the active ones, 3 expansion, 1 new construction and 1 revamp / retrofit.
Post‑hoc ATTAIN‑1 modelling: oral orforglipron cut predicted 10‑year type 2 diabetes risk up to 57% and cardiovascular risk up to 18% versus placebo at 72 weeks.
Once‑daily oral GLP‑1 cut MACE vs insulin glargine, lowered A1C by 1.6% at 52 weeks and produced mean weight loss of 8.1 kg with durable effects to 104 weeks.
An indirect, covariate‑adjusted comparison of SURMOUNT‑1 and STEP UP data shows larger mean and categorical weight‑loss benefits with tirzepatide 10 mg and 15 mg at 72 weeks.
FDA clears once‑weekly basal insulin that reduces injection frequency vs daily therapy; Phase 3 QWINT trials in >3,400 adults showed non‑inferior A1C vs glargine and degludec.
Oral GLP‑1 orforglipron reduced A1C and body weight more than oral semaglutide, dapagliflozin or placebo across three Phase‑3 trials; FDA filing planned by end of Q2 2026.
Orforglipron produced meaningful body‑weight and waist reductions across menopausal stages in ATTAIN‑1 and ATTAIN‑2, including women with type 2 diabetes.
Successor returns July 1 as EVP and assumes CFO duties Sept 1; outgoing CFO stays through Jan 2027 to aid transition. Successor has 30+ yrs finance leadership, ex‑CFO at Galderma, Shire, Sulzer.
Expands Puerto Rico biologics facility to boost U.S. production, deploy next‑gen technologies, support workforce development and construction jobs, and strengthen medicine supply‑chain resilience
Reese retires June 30, 2026. Effective June 1, leadership reshuffle: James Bradner named EVP R&D, AI & Data; Sean Bruich CTO; Murdo Gordon EVP Global Markets & Policy; Paul Burton remains CMO.
ACHIEVE-4: Foundayo non-inferior vs insulin glargine for MACE-4 (HR 0.84); improved A1C (-1.6 vs -1.0) and weight (-8.8% vs +1.7%) at 52 wks; 57% lower all-cause death; GI AEs; FDA filing planned.
